CLINICAL ROLE -
Video
Author(s):
Alexandra S. Wolff, PharmD, BCOP, comments on her experience with CPX-351 in clinical practice and the potential to combine CPX-351 with targeted agents for AML.
Ruxolitinib Discontinuation at Conditioning Does Not Increase GVHD Risk in Myelofibrosis
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
GPRC5D-Targeted CAR T-Cell Therapy Shows Promise After BCMA Treatment Failure
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Updates in the Management of Transplant-Ineligible Patients With Multiple Myeloma
From Mutation to Management: Risk Stratification, the Power of JAK Inhibition, and the Pharmacist’s Role